Biomedica Immunoassays

565 €

Contact us!


Most referenced ELISA!


Assay characteristics:

Cat.No.: BI-20492
Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
Sample type:Serum, plasma (EDTA, heparin), urine protocol available
Standard range:0-240 pmol/l (6 serum based standards)
Standard points:0/15/30/60/120/240 pmol/l
Control:1 serum based control
Sample size:20 µl / well
Incubation time:Overnight / 1 h / 30 min
Unit conversion:1 pg/ml = 0.044 pmol/l (MW: 22.5 kDa)

LOD: 3.2 pmol/l (0 pmol/l + 3 SD); LLOQ: < 7.5 pmol/l

Intra-assay (n=8) ≤ 7%, Inter-assay (n=6) ≤ 10%

The mean recovery of recombinant Sclerostin in human serum samples (n=6) is 94%.

Dilution linearity:
Endogenous Sclerostin:
The mean dilution linearity of endogenous Sclerostin in human serum samples (n=4) is 110% for dilution factors 1+1, 1+3, 1+7.

Recombinant Sclerostin:
The mean dilution linearity for recombinant Sclerostin in human serum samples (n=3) is 98% for dilution factors 1+1, 1+3.

Cross reactivity: 
The assay does not detect Noggin.
The assay does not detect Wise (SOSTDC1).

Species cross reactivity:
Rat, mouse: The assay does not detect rat or mouse Sclerostin.
Primates: The sequence homology of human Sclerostin to various primate species is >95%. It is likely that the assay can be used for these species. Internal validations have not been carried out. However, data from other laboratories show positive results.

Serum  values from apparently healthy individuals:
Median (serum, n=411): 24.14. pmol/l. 
It is recommended to establish the normal range for each laboratory. 

Principle of the assay: 

Manual ELISAs - easily adaptable for automation! 

Back to top


Click links for:

BI-20492 Sclerostin ELISA IFU 

Biomedica Analytical Service Quotation Form

Back to top


Click here for assay validation data (S/R, dilution linearity, precision, ...).

Back to top


Canonical Wnt-signalling plays an important role in the regulation of bone homeostasis by promoting the development of osteoblasts. Negative regulators of the Wnt pathway are important new therapeutic targets for the treatment of diseases with enhanced bone resorption. One of these molecules is Sclerostin, a 22.5 kD secreted glycoprotein, which acts by binding to the Wnt-coreceptor LRP5 thus preventing the binding of Wnt molecules.

Sclerostin is nearly exclusively produced in osteocytes. Therefore it is considered a clinical marker which provides highest bone specificity.

Click here for MSDS    
Click here for PRODUCT LEAFLET

Back to top


Click here for reference list.

Sclerostin in Nephrology - Info Leaflet
Sclerostin in Aortic Valve Calcification, Renal Disease, and Diabetes
Sclerostin & Fracture
Association of Sclerostin & Physical Activity

Calcification Propensity of Serum is Independent of Excretory Renal Function
Bernhard Bielesz, Thomas Reiter, Rodrig Marculescu, Andreas Gleiss, Marija Bojic, Heidi Kieweg, and Daniel Cejka
Sci Rep. 2017; 7: 17941.
PMID: 5738386

Periostin and sclerostin levels in juvenile Paget’s disease
Stergios A. Polyzos, Polyzois Makras, Athanasios D. Anastasilakis, Gesthimani Mintziori, Marina Kita, Athanasios Papatheodorou Panagiotis Kokkoris and Evangelos Terpos
Clin Cases Miner Bone Metab. 2017 May-Aug; 14(2): 269–271.
PMCID: PMC5726226

A Cytokine-Like Protein Dickkopf-Related Protein 3 Is Atheroprotective
Baoqi Yu, 
Stefan Kiechl, Dan Qi, Xiaocong Wang, Yanting Song, Siegfried Weger, Agnes Mayr, Alexandra Le Bras, Eirini Karamariti, Zhongyi Zhang, Ivan del Barco Barrantes, Christof Niehrs, Georg Schett, Yanhua Hu, Wen Wang, Johann Willeit, Aijuan Qu,  and Qingbo Xu,
Circulation. 2017 Sep 12; 136(11): 1022–1036.
PMCID: PMC5598907

Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation
Lida Tartaglione, Marzia Pasquali, Silverio Rotondi, Maria Luisa Muci, Cristiana Leonangeli, Alessio Farcomeni, Valeria Fassino, and Sandro Mazzaferro
PLoS One. 2017; 12(5): e0178637.
PMCID: PMC5448809

Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD
Geert J. Behets, Liesbeth Viaene, Björn Meijers, Frank Blocki, Vincent M. Brandenburg, Anja Verhulst, Patrick C. D’Haese, and Pieter Evenepoel
PMID: 28493902

Sclerostin measurement in human disease: Validity and current limitations.
Aline G. Costa, Serge Cremers, John P. Bilezikian
Bone, 2017, 24-28
PMID: 27742501

Glucocorticoid therapy causes contradictory changes of serum Wnt signaling-related molecules in systemic autoimmune diseases
Mai Kawazoe, Kaichi Kaneko, Kotaro Shikano, Natsuko Kusunoki, Toshihiro Nanki, Shinichi Kawai
Clinical Rheumatology, 2017, 1-10
PMID: 28551822

Atypical skeletal manifestations of rickets in a familial hypocalciuric hypercalcemia patient
Bo Wu, Ou Wang, Yan Jiang, Mei Li, Xiaoping Xing, Weibo Xia,
Bone research, 2017
PMCID: PMC5486235

Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis
Carlson N., Mortensen O.H., Axelsen M., Pedersen R.S., Heaf J.G.
Blood Purification, 2017, 122-128
PMID: 28690912

Low periostin levels in adult patients with Langerhans cell histiocytosis are independently associated with the disease activity
Athanasios D.Anastasilakis, Stergios A.Polyzos,  Marina Tsoli, Athanasios Papatheodorou, Panagiotis Kokkoris, Gregory Kaltsas, Evangelos Terpos, Polyzois Makras
Metabolism, 2017, 198-201
PMID: 28521873

Serum sclerostin levels in renal cell carcinoma patients with bone metastases
C. Wibmer, K. Amrein, A. Fahrleitner-Pammer, M. M. Gilg, A. Berghold, G. C. Hutterer, W. Maurer-Ertl,  A. Gerger, A. Leithner, M. Pichler and J. Szkandera
Sci Rep. 2016; 6: 33551.
PMCID: PMC5036091

Direct effects of physical training on markers of bone metabolism and serum sclerostin concentrations in older adults with low bone mass
Gabriella Császárné Gombos, Viktória Bajsz, Emese Pék, Béla Schmidt, Eszter Sió, Bálint Molics, and József Betlehem
BMC Musculoskelet Disord. 2016; 17: 254.
PMCID: PMC4899888

Idiopathic Acquired Osteosclerosis In A Middle-aged Woman With Systemic Lupus Erythematosus
Núria Guañabens, Steven Mumm, Laia Gifre, Silvia Ruiz Gaspà, Jennifer L. Demertzis, Marina Stolina, Deborah V. Novack and Michael P Whyte
J Bone Miner Res. 2016 Sep; 31(9): 1774–1782.
PMCID: PMC5010446

Serum Sclerostin as an Independent Marker of Peripheral Arterial Stiffness in Renal Transplantation Recipients
Bang-Gee Hsu, Hung-Hsiang Liou, Chung-Jen Lee, Yen-Cheng Chen, Guan-Jin Ho, and Ming-Che Lee
Medicine (Baltimore). 2016 Apr; 95(15): e3300.
PMCID: PMC4839814

Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort.
Karine Briot, Adrien Etcheto, Corinne Miceli-Richard, Maxime Dougados, and Christian Roux
Rheumatology, 2016; 55: 335 – 342
PMID: 26361878

Serum Sclerostin Levels in Patients with Human Immunodeficiency Virus Infection and Their Association with Bone Turnover Markers and Bone Mineral Densitometry
Abdulrahman Y. Almansouri,corresponding author Mohammed E. Abdulfatah, Omar H. Baaqil, Alaa A. Bakheet, Sarah A. Turki, Mamdouh M. Kotb, Alaa Althubaiti, Majed M. Almaghrabi, Abdulrahman M. Althubaiti, Badr M. Madani, and Ali S. M. Jawad
J Bone Metab. 2016 Feb; 23(1): 16–22.
PMCID: PMC4791433

Sclerostin as a novel marker of bone turnover in athletes
A Zagrodna, P Jóźków, M Mędraś, M Majda, and M Słowińska-Lisowska
Biol Sport. 2016 Mar; 33(1): 83–87
PMCID: PMC4763547

Sclerostin serum levels in patients with systemic autoimmune diseases
Concepción Fernández-Roldán, Fernanda Genre, Raquel López-Mejías, Begoña Ubilla, Verónica Mijares, Daniel Sánchez Cano, Concepción López Robles, José Luis Callejas-Rubio, Raquel Ríos Fernández, Manuela Expósito Ruiz, Miguel Á González-Gay, and Norberto Ortego Centeno
Bonekey Rep. 2016; 5: 775.
PMCID: PMC4747078

Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort
Raphaèle Seror, Saida Boudaoud, Stephan Pavy, Gaetane Nocturne, Thierry Schaeverbeke, Alain Saraux, Philippe Chanson, Jacques-Eric Gottenberg, Valérie Devauchelle-Pensec, Gabriel J. Tobón, Xavier Mariette, and Corinne Miceli-Richarda
Sci Rep. 2016; 6: 18421.
PMCID: PMC4726234

How Accurate is Your Sclerostin Measurement? Comparison Between Three Commercially Available Sclerostin ELISA Kits
Isabelle Piec, Christopher Washbourne, Jonathan Tang, Emily Fisher, Julie Greeves, Sarah Jackson, and William D. Fraser
Calcif Tissue Int. 2016; 98: 546–555.
PMCID: PMC4860200

Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients
Sebastian F. Mause, Annika Deck, Mark Hennies, Nadine Kaesler, Pieter Evenepoel, William A. Boisvert, Ulf Janssen and Vincent M. Brandenburg
Discoveries (Craiova). 2016; 4(1): e55.
PMCID: PMC4829955

Bone metabolism and renal stone risk during International Space Station missions
Scott M.Smith, Martina Heer, Linda C.Shackelford, Jean D.Sibonga, JordanSpatz, Robert A.Pietrzyk, Edgar K.Hudson, Sara R.Zwart.
Bone, 2015;712-720.
PMID: 26456109

Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort
Gaetane Nocturne, Stephan Pavy, Saida Boudaoud, Raphaèle Seror, Philippe Goupille, Philippe Chanson, Désirée van der Heijde, Floris van Gaalen, Francis Berenbaum, Xavier Mariette, Karine Briot, Antoine Feydy, Pascal Claudepierre, Philippe Dieudé, Joanne Nithitham, Kimberly E. Taylor, Lindsey A. Criswell, Maxime Dougados, Christian Roux, and Corinne Miceli-Richard
PLoS One. 2015; 10(8): e0134974.

PMCID: PMC4552086

Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone
Elżbieta Skowrońska-Jóźwiak, Krzysztof C. Lewandowski, Zbigniew Adamczewski, Kinga Krawczyk-Rusiecka, and Andrzej Lewiński
Int J Endocrinol. 2015; 2015: 948384.
PMCID: PMC4561097

Changes in Serum Levels of Myokines and Wnt-Antagonists after an Ultramarathon Race
Katharina Kerschan-Schindl, Markus M. Thalmann, Elisabeth Weiss, Maria Tsironi, Ursula Föger-Samwald, Johann Meinhart, Katerina Skenderi, and Peter Pietschmann
PLoS One. 2015; 10(7): e0132478.
PMCID: PMC4493015

Increased Sclerostin Levels after Further Ablation of Remnant Estrogen by Aromatase Inhibitors
Wonjin Kim, Yoonjung Chung, Se Hwa Kim, Sehee Park, Jae Hyun Bae, Gyuri Kim, Su Jin Lee, Jo Eun Kim, Byeong-Woo Park, Sung-Kil Lim, and Yumie Rhee
Endocrinol Metab (Seoul). 2015 Mar; 30(1): 58–64.
PMCID: PMC4384667

Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism
Giuseppe Daniele, Deidre Winnier, Andrea Mari, Jan Bruder, Marcel Fourcaudot, Zuo Pengou, Devjit Tripathy, Christopher Jenkinson, and Franco Folli
Diabetes Care,
2015; 38: 1509 - 1517.
PMID: 26456109

Association of Serum Sclerostin with Vascular Calcification in African Ancestry Men
Allison L Kuipers, Iva Miljkovic, J Jeffery Carr, James G Terry, Cara S Nestlerode, Yaorong Ge, Clareann H Bunker, Alan L Patrick, and Joseph M Zmuda
2015; 131: AP298.
PMID: 25618029

Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels
Eugènia Negredo, Adolfo Diez-Pérez, Anna Bonjoch, Pere Domingo, Núria Pérez-Álvarez, Mar Gutierrez, Gracia Mateo, Jordi Puig, Patricia Echeverría, Roser Escrig, and Bonaventura Clotet
J. Antimicrob. Chemother.,
2015; 70: 2104 - 2107.
PMID: 25769303

Serum Sclerostin levels are reduced by treatment with online postdilution hemodiafiltration
Camiel LM de Roij van Zuijdewijn, Muriel PC Grooteman, Marc G Vervloet, Menso J Nube, Peter J Blankestijn, Marinus A van den Dorpel, Denis Fouque, Solenne Pelletier, Michiel L Bots, and Piet M ter Wee
Nephrol. Dial. Transplant.,
2015; 30: iii324.

High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis
Hartmut H. Malluche, Gustav Blomquist, Marie-Claude Monier-Faugere, Thomas L. Cantor, and Daniel L. Davenport
J. Am. Soc. Nephrol.,
2015; 10.1681/ASN.2014070686.
PMID: 25838468

Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study
Tugba Tuylu, Ismail Sari, Dilek Solmaz, Didem Leyla Kozaci, Servet Akar, Necati Gunay, Fatos Onen, and Nurullah Akkoc
Clinics (Sao Paulo). 2014 Oct; 69(10): 688–693.
PMCID: PMC4221327

Circulating Sclerostin and Irisin Are Related and Interact with Gender to Influence Adiposity in Adults with Prediabetes
Theerawut Klangjareonchai, Hataikarn Nimitphong, Sunee Saetung, Nuttapimon Bhirommuang, Rattanapan Samittarucksa, Suwannee Chanprasertyothin, Rattana Sudatip, and Boonsong Ongphiphadhanakul
Int J Endocrinol. 2014; 2014: 261545.
PMCID: PMC4167818

The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
Se Hwa Kim, Soo Young Yoon, Sung-Kil Lim, and Yumie Rhee
Int J Endocrinol. 2014; 2014: 715908.
PMCID: PMC4099222

Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5
C. A. Simpson, 
D. Foer, G. S. Lee, J. Bihuniak, B. Sun, R. Sullivan, J. Belsky, and K. L. Insogna
Osteoporos Int. 2014 Oct; 25(10): 2383–2388.
PMCID: PMC4659359

Serum Sclerostin in Hepatitis C Virus Infected Patients
Emilio González-Reimers, Javier López-Prieto, Ricardo Pelazas-González, M.Remedios Alemán-Valls, María José de la Vega-Prieto, Carlos Jorge-Ripper, M. Carmen Durán-Castellón, and F Santolaria-Fernández
J Bone Metab. 2014 Feb; 21(1): 69–75.
PMCID: PMC3970296

Serum Sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.
J Clin Endocrinol, 2014; 99(10): E1854–E1861
PMID: 25057883

Gender differences in sclerostin and clinical characteristics in type 1 diabetes mellitus
Antonino Catalano, Basilio Pintaudi, Nancy Morabito, Giacoma Di Vieste, Loretta Giunta, Maria Lucia Bruno, Domenico Cucinotta, Antonino Lasco, and Antonino Di Benedetto
Eur. J. Endocrinol.,
2014; 171: 293 - 300.
PMID: 24891138

Biomarkers of Bone Metabolism in Ankylosing Spondylitis in Relation to Osteoproliferation and Osteoporosis
Eva Klingberg, Merja Nurkkala, Hans Carlsten, and Helena Forsblad-d’Elia
J Rheumatol,
2014; 41: 1349 - 1356.
PMID: 24931960

Effect of supplemental vitamin D and calcium on serum sclerostin levels
Bess Dawson-Hughes, Susan S Harris, Lisa Ceglia, and Nancy J Palermo
Eur. J. Endocrinol.,
2014; 170: 645 - 650.
PMID: 24488080

Renal elimination of sclerostin increases with declining kidney function
Daniel Cejka, Rodrig Marculescu, Nicolas Kozakowski, Max Plischke, Thomas Reiter, Alois Gessl, and Martin Haas
J. Clin. Endocrinol
. Metab., 2014; 99: 248-255.
PMID: 24187403

The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus
Agostino Gaudio, Filippo Privitera, Ivana Pulvirenti, Elena Canzonieri, Rosario Rapisarda, and Carmelo E Fiore
Diabetes and Vascular Disease Research, 2014;
11: 48-52.
PMID: 24227537

Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
Liesbeth Viaene, Geert J. Behets, Kathleen Claes, Bjorn Meijers, Franck Blocki, Vincent Brandenburg, Pieter Evenepoel, and Patrick C. D'Haese
Nephrol. Dial. Transplant.,
2013; 28: 3024 – 3030
PMID: 23605174

Traditional and Novel Bone Remodeling Markers in Premenopausal and Postmenopausal Women
Sonsoles Botella, Patricia Restituto, Ignacio Monreal, Inmaculada Colina, Amparo Calleja, and Nerea Varo
J. Clin. Endocrinol. Metab.,
2013; 98: E1740 - E1748.
PMID: 24001743

Elevated Sclerostin Levels Are Associated With Vertebral Fractures in Patients With Type 2 Diabetes Mellitus
Masahiro Yamamoto, Mika Yamauchi, and Toshitsugu Sugimoto
J. Clin. Endocrinol. Metab.,
2013; 98: 4030 - 4037.
PMID: 23894157

Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.
Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, and Saeda MY
Bone (2013), 56: 355-362.
PMID: 23845326

Association of Circulating Sclerostin With Bone Mineral Mass, Microstructure, and Turnover Biochemical Markers in Healthy Elderly Men and Women
Claire Durosier, Antoon van Lierop, Serge Ferrari, Thierry Chevalley, Socrates Papapoulos, and René Rizzoli
J. Clin. Endocrinol. Metab.,
2013; 98: 3873 - 3883.
PMID: 23864703

Atherosclerotic Disease in Type 2 Diabetes Is Associated With an Increase in Sclerostin Levels
Sonia Morales-Santana, Beatriz García-Fontana, Antonia García-Martín, Pedro Rozas-Moreno, José Antonio García-Salcedo, Rebeca Reyes-García, and Manuel Muñoz-Torres
Diabetes Care,
2013; 36: 1667-1674.
PMID: 23288857

Relative Influence of Heritability, Environment and Genetics on Serum Sclerostin
Allison L. Kuipers, Yingze Zhang, Shibing Yu, Candace M. Kammerer, Cara S. Nestlerode, Yanxia Chu, Clareann H. Bunker, Alan L. Patrick, 4 Victor W. Wheeler, Iva Miljkovic, and Joseph M. Zmuda
Osteoporos Int. 2014 Mar; 25(3): 905–912.

Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naïve Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-head Clinical Trial
Athanasios D. Anastasilakis, Stergios A. Polyzos, Athina Gkiomisi, Ilias Bisbinas, Spyridon Gerou, and Polyzois Makras
J. Clin. Endocrinol. Metab.,
PMID: 23788684

The Relation between Renal Function and Serum Sclerostin in Adult Patients with CKD
Solenne Pelletier, Laurence Dubourg, Marie-Christine Carlier, Aoumeur Hadj-Aissa, and Denis Fouque
Clin. J. Am. Soc. Nephrol.,
2013; 8: 819-823.
PMID: 23430206

Zoledronic Acid Acutely Increases Sclerostin Serum Levels in Women With Postmenopausal Osteoporosis
Antonino Catalano, Nancy Morabito, Giorgio Basile, Santa Brancatelli, Domenico Cucinotta, and Antonino Lasco
J. Clin. Endocrinol. Metab.,
2013; 98: 1911-1915.
PMID: 23596142

Serum Sclerostin in Alcoholics: A Pilot Study
E. González-Reimers, C. Martín-González, M.J. de la Vega-Prieto, R. Pelazas-González, C. Fernández-Rodríguez, J. López-Prieto, J. Alvisa-Negrín, and F. Santolaria-Fernández
Alcohol Alcohol.,
May 2013; 48: 278-282.
PMID: 23296214

High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The center of excellence for osteoporosis research study.
MS Ardawi, AA Rouzi, SA Al-Sibiani, NS Al-Senani, MH Qari, and SA Mousa
J Bone Miner Res,
Dec 2012; 27(12): 2592-2602.
PMID: 22836717

High Circulating Sclerostin is Present in Patients with Thalassemia-associated Osteoporosis and Correlates with Bone Mineral Density.
E Voskaridou, D Christoulas, E Plata, C Bratengeier, A Anastasilakis, V Komninaka, D Kaliontzi, M Gkotzamanidou, SA Polyzos, M Dimopoulou, and E Terpos
Horm Metab Res,
Nov 2012; 44(12): 909-913.
PMID: 22581647

Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
D Gatti, O Viapiana, E Fracassi, L Idolazzi, C Dartizio, MR Povino, S Adami, and M Rossini
J Bone Miner Res,
Nov 2012; 27(11): 2259-2263.
PMID: 22692843

Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels.
EB Skowro Ska-Jo Wiak, K Krawczyk-Rusiecka, KC Lewandowski, Z Adamczewski, and A Lewi Ski
Thyroid Res,
Nov 2012; 5(1): 14.
PMID: 23146624

Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase
Dagmar-Christiane Fischer, Anne Mischek, Sabrina Wolf, Anja Rahn, Birgit Salweski, Guenther Kundt, and Dieter Haffner
Ann Clin Biochem,
Nov 2012; 49: 546-553.
PMID: 22984195

Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
CG Saad, AC Ribeiro, JC Moraes, L Takayama, CR Goncalves, MB Rodrigues, RM Oliveira, CA Silva, E Bonfa, and RM Pereira
Arthritis Res Ther,
Oct 2012; 14(5): R216.
PMID: 23062122

Strongly enhanced levels of sclerostin during human fracture healing.
K Sarahrudi, A Thomas, C Albrecht, and S Aharinejad
J Orthop Res,
Oct 2012; 30(10): 1549-1555.
PMID: 22508529

Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis
Ali Taylan, Ismail Sari, Baris Akinci, Safak Bilge, Didem Kozaci, Servet Akar, Ayfer Colak, Hulya Yalcin, Necati Gunay, and Nurullah Akkoc
BMC Musculoskelet Disord. 2012; 13: 191.
PMCID: PMC3492209

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
E Terpos, D Christoulas, E Katodritou, C Bratengeier, M Gkotzamanidou, E Michalis, S Delimpasi, A Pouli, J Meletis, E Kastritis, K Zervas, and MA Dimopoulos
Int J Cancer,
Sep 2012; 131(6): 1466-1471.
PMID: 22052418

Physical Activity in Relation to Serum Sclerostin, Insulin-Like Growth Factor-1, and Bone Turnover Markers in Healthy Premenopausal Women: A Cross-Sectional and a Longitudinal Study
Mohammed-Salleh M. Ardawi, Abdulrahim A. Rouzi, and Mohammed H. Qari
J. Clin. Endocrinol. Metab.,
Oct 2012; 97: 3691-3699.
PMID: 22865898

Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus
Agostino Gaudio, Filippo Privitera, Katia Battaglia, Venerando Torrisi, Maria Helga Sidoti, Ivana Pulvirenti, Elena Canzonieri, Giovanni Tringali, and Carmelo Erio Fiore
J. Clin. Endocrinol. Metab.,
Oct 2012; 97: 3744-3750.
PMID: 22855334

Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
S Piemonte, E Romagnoli, C Bratengeier, W Woloszczuk, A Tancredi, J Pepe, C Cipriani, and S Minisola
J Endocrinol Invest,
Oct 2012; 35(9): 866-868.
PMID: 22842667

Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis
Diederik P C de Rooy, Nataliya G Yeremenko, Anthony Gerard Wilson, Rachel Knevel, Elisabet Lindqvist, Tore Saxne, Annemarie Krabben, Martha K Leijsma, Nina A Daha, S Tsonaka, A Zhernakova, J J Houwing-Duistermaat, Tom W J Huizinga, René E M Toes, Dominique L P Baeten, E Brouwer, and Annette H M van der Helm-van Mil
Ann Rheum Dis,
Oct 2012; 10.1136/annrheumdis-2012-202184.
PMID: 23041840

Serum Sclerostin Increases in Healthy Adult Men during Bed Rest
J. M. Spatz, E. E. Fields, E. W. Yu, P. Divieti Pajevic, M. L. Bouxsein, J. D. Sibonga, S. R. Zwart, and S. M. Smith
J. Clin. Endocrinol. Metab., Sep 2012; 97: E1736-E1740.
PMID: 22767636

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy.
E Terpos, D Christoulas, E Katodritou, C Bratengeier, M Gkotzamanidou, E Michalis, S Delimpasi, A Pouli, J Meletis, E Kastritis, K Zervas, and MA Dimopoulos
Int J Cancer, Sep 2012; 131(6): 1466-1471
PMID: 22052418

Association of Circulating Sclerostin Levels with Fat Mass and Metabolic Disease—Related Markers in Japanese Postmenopausal Women
Tomohiko Urano, Masataka Shiraki, Yasuyoshi Ouchi, and Satoshi Inoue
J. Clin. Endocrinol. Metab., Aug 2012; 97: E1473-E1477.


Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women.
Z Sheng, D Tong, Y Ou, H Zhang, Z Zhang, S Li, J Zhou, J Zhang, and E Liao
Clin Endocrinol (Oxf), Jun 2012; 76(6): 797-801.
PMID: 22151063

Nitroglycerin May Improve Bone Mass by Suppressing Sclerostin Levels
Aarthi Arasu, Celeste J Hamilton, Steven R Cummings, Richard Eastell, and Sophie A Jamal
Endocr. Rev.,
Jun 2012; 33: SAT-335.

Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study.
MS Ardawi, AM Al-Sibiany, TM Bakhsh, AA Rouzi, and MH Qari
Osteoporos Int,
Jun 2012; 23(6): 1789-1797.
PMID: 22041864

Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Luigi Gennari, Daniela Merlotti, Roberto Valenti, Elena Ceccarelli, Martina Ruvio, Maria G. Pietrini, Cosimo Capodarca, Maria Beatrice Franci, Maria Stella Campagna, Anna Calabro, Dorica Cataldo, Konstantinos Stolakis, Francesco Dotta,and Ranuccio Nuti
J Clin Endocrinol Metab, May 2012, 97(5):1737–1744.
PMID: 22399511

High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis
Gisela Ruiz Heiland,Heiner Appel,Denis Poddubnyy, Jochen Zwerina,Axel Hueber,Hildrun Haibel, Xenofon Baraliakos,Joachim Listing, Martin Rudwaleit,Georg Schett, Joachim Sieper
Ann Rheum Dis
, 2012;71:572–574.
PMID: 22186710

Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.
YE Chung, SH Lee, SY Lee, SY Kim, HH Kim, FS Mirza, SK Lee, JA Lorenzo, GS Kim, and JM Koh.
Osteoporos Int,
Apr 2012; 23(4): 1235-1243.
PMID: 21660558

Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women-the six-month effect of risedronate and teriparatide.
SA Polyzos, AD Anastasilakis, C Bratengeier, W Woloszczuk, A Papatheodorou, and E Terpos.
Osteoporos Int, Mar 2012; 23(3): 1171-1176.
PMID: 21305266

Physical training increases osteoprotegerin in postmenopausal women.
I Bergstrom, P Parini, SA Gustafsson, G Andersson, and J Brinck
J Bone Miner Metab,
Mar 2012; 30(2): 202-207.


Back to top